R. Paul Flynn - Mar 8, 2022 Form 4 Insider Report for DEXCOM INC (DXCM)

Signature
By: Jereme Sylvain For: Paul Flynn
Stock symbol
DXCM
Transactions as of
Mar 8, 2022
Transactions value $
-$1,204,765
Form type
4
Date filed
3/10/2022, 06:24 PM
Previous filing
Dec 17, 2021
Next filing
Dec 8, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DXCM Common Stock Award $5.30 +5.3K +38.24% $0.00* 19.2K Mar 8, 2022 Direct F1, F2
transaction DXCM Common Stock Disposed to Issuer -$434K -1.07K -5.58% $406.06 18.1K Mar 9, 2022 Direct F2, F3
transaction DXCM Common Stock Disposed to Issuer -$452K -1.11K -6.16% $406.06 17K Mar 9, 2022 Direct F2, F3
transaction DXCM Common Stock Disposed to Issuer -$318K -784 -4.62% $406.06 16.2K Mar 9, 2022 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting in three equal annual installments from the date of grant. Share units represent a contingent right to receive one share of DexCom, Inc. Common Stock.
F2 Included in this number are 13,936 unvested restricted stock units, 5,297 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 2,925 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 3,756 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 1,958 of which were granted on March 8, 2020 and shall vest through March 8, 2023.
F3 Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.